An integrated approach to the treatment of pelvic pain associated with adenomyosis

In: REPRODUCTIVE ENDOCRINOLOGY · 2021 · pp. 53–60 · doi:10.18370/2309-4117.2021.59.53-60 · W3185462314
article OA: diamond CC0 ⤵ 2 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-06

This study found that adding L-arginine to dydrogesterone treatment significantly reduced pelvic pain in women with adenomyosis compared to dydrogesterone alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-06 · read from full text

This study evaluated whether adding a nitric oxide donor (L-arginine; Tivortin) to dydrogesterone improves pelvic pain in 63 women diagnosed with adenomyosis, assessed using the Visual Analogue Scale, McGill Pain Questionnaire, and SF-36 at baseline, after 1 and 3 months of treatment, and again 3 months after stopping. Both groups achieved therapeutic effects, but the group receiving dydrogesterone plus L-arginine had a significant reduction in pelvic pain after 3 months, with no pain recurrence, whereas the standard dydrogesterone-only group had a more prolonged progestogen intake; further improvement occurred in the standard group at 6 months follow-up. The main caveat is that the paper provides limited detail on study design beyond simple randomization and does not explicitly describe blinding, control of concomitant factors, or adverse events. This paper is centrally about adenomyosis — it tests nitric oxide donor (L-arginine) as an add-on to dydrogesterone for pelvic pain in adenomyosis, directly addressing dysmenorrhoea and intermenstrual pelvic pain.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Dysmenorrhoea and intermenstrual pelvic pain are the most common symptoms of clinical manifestations of adenomyosis, which significantly impair the quality of women’s life. Adequate and long-term pain correction and alternative therapeutic approaches became extremely important for patients with adenomyosis during the COVID-19 pandemic. Research objective: to examine the clinical efficacy of nitric oxide donor (L-arginine) in the complex treatment of pelvic pain syndrome associated with adenomyosis.Materials and methods. The study included 63 women diagnosed with adenomyosis. Patients were divided into 2 groups by simple randomization: I (D) group (n = 31) received dydrogesterone 30 mg from 5 to 25 days of the menstrual cycle, II (D+T) group (n = 32) in addition to dydrogesterone received a nitric oxide donor L-arginine (Тivortin) according to the scheme. Pelvic pain was assessed before treatment with a Visual Analogue Scale and a McGill Pain Questionnaire, and an assessment of the overall pain impact on women's well-being was based on the SF-36 Health Status Survey. The effectiveness of pelvic pain therapy was assessed after the first and third months of treatment, as well as three months after the end of therapy with the above methods.Results. Researchers achieved a therapeutic effect in the treatment of chronic pelvic pain in both study groups, but in group II (D + T) after 3 months of treatment there was a significant reduction in pelvic pain, while patients of the standard therapy group have prolonged progestogen intake. There was a further improvement in the clinical condition in group I (D) after 6 months of follow-up, as well as no recurrence of pain in group II (D + T).Conclusions. The results of study demonstrate a significant effect of Tivortin as part of complex therapy on the rate of achievement and duration of therapeutic effect in the treatment of pelvic pain associated with adenomyosis.
Full text 9,953 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Materials

and methods. The study included 63 women diagnosed with adenomyosis. Patients were divided into 2 groups by simple randomization: I (D) group (n = 31) received dydrogesterone 30 mg from 5 to 25 days of the menstrual cycle, II (D+T) group (n = 32) in addition to dydrogesterone received a nitric oxide donor L-arginine (Тivortin) according to the scheme. Pelvic pain was assessed before treatment with a Visual Analogue Scale and a McGill Pain Questionnaire, and an assessment of the overall pain impact on women's well-being was based on the SF-36 Health Status Survey. The effectiveness of pelvic pain therapy was assessed after the first and third months of treatment, as well as three months after the end of therapy with the above methods. Results. Researchers achieved a therapeutic effect in the treatment of chronic pelvic pain in both study groups, but in group II (D + T) after 3 months of treatment there was a significant reduction in pelvic pain, while patients of the standard therapy group have prolonged progestogen intake. There was a further improvement in the clinical condition in group I (D) after 6 months of follow-up, as well as no recurrence of pain in group II (D + T). Conclusions. The results of study demonstrate a significant effect of Tivortin as part of complex therapy on the rate of achievement and duration of therapeutic effect in the treatment of pelvic pain associated with adenomyosis.

References

- Donnez, J., Donnez, O., Dolmans, M.M. “Introduction: Uterine adenomyosis, another enigmatic disease of our time.” Fertil Steril 109.3 (2018): 369–70. - Seliukova, N.Y., Gladkova, A.I., Koreneva, E.M., et al. “Stress and reproductive disorders: Modern views on the problem and own research experience.” Problemi Endokrinnoi Patologii 1 (2019): 87–94. - Harada, T., et al. “The Impact of Adenomyosis on Women’s Fertility.” Pediatr Emerg Care 33.12 (2017): 792–3. - Zhai, J., Vannuccini, S., Petraglia, F., Giudice, L.C. “Adenomyosis: Mechanisms and Pathogenesis.” Semin Reprod Med 38.2–3 (2020): 129–43. - Harmsen, M.J., Wong, C.F.C., Mijatovic, V., et al. “Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: A systematic review.” Human Reproduction Update 25 (2019): 647–71. - Vannuccini, S., Tosti, C., Carmona, F., et al. “Pathogenesis of adenomyosis: an update on molecular mechanisms.” Reprod Biomed Online 35.5 (2017): 592–601. DOI: 10.1016/j.rbmo.2017.06.016 - Coluzzi, F., Marinangeli, F., Pergolizzi, J. “Managing chronic pain patients at the time of COVID-19 pandemic.” Minerva Anestesiologica 86 (2020): 797–9. - Hron, J.D., Parsons, C.R., Williams, L.A., et al. “Rapid Implementation of an Inpatient Telehealth Program during the COVID-19 Pandemic.” Appl Clin Inform 11.3 (2020): 452–9. - Shanthanna, H., Strand, N.H., Provenzano, D.A., et al. “Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel.” Anaesthesia 75 (2020): 935–44. - Kemp, H.I., Corner, E., Colvin, L.A. “Chronic pain after COVID-19: implications for rehabilitation.” British Journal of Anaesthesia 125 (2020): 436–40. - Cohen, S.P., Baber, Z.B., Buvanendran, A., et al. “Pain management best practices from multispecialty organizations during the COVID-19 pandemic and public health crises.” Pain Med (United States) 21.7 (2020): 1331–46. - Emerick, T., Alter, B., Jarquin, S., et al. “Telemedicine for chronic pain in the COVID-19 era and beyond.” Pain Medicine (United States) 21 (2020): 1743–8. - Hillen, F., Griffioen, A.W. “Tumour vascularization: Sprouting angiogenesis and beyond.” Cancer and Metastasis Reviews 26 (2007): 489–502. - Vannuccini, S., Petraglia, F. “Recent advances in understanding and managing adenomyosis.” F1000Research 8 (2019). - Yan, R., Zhang, Y., Li, Y., et al. “Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.” Science 367.6485 (2020): 1444–8. - Pons, S., Fodil, S., Azoulay, E., Zafrani, L. “The vascular endothelium: The cornerstone of organ dysfunction in severe SARS-CoV-2 infection.” Critical Care 24 (2020). - Leite, A.R., Borges-Canha, M., Cardoso, R., et al. “Novel Biomarkers for Evaluation of Endothelial Dysfunction.” Angiology 71 (2020): 397–410. - Kolenko, O.V., Pomytkina, N.V., Sorokin, E.L, et al. “Correlation between biochemical markers of endothelial dysfunction, free radical oxidation and morphometric parameters of macular retina in pregnant women with preeclampsia.” Vestn Oftalmol 135.2 (2019): 39–46. - Vannuccini, S., Luisi, S., Tosti, C., et al. “Role of medical therapy in the management of uterine adenomyosis.” Fertility and Sterility 109 (2018): 398–405. - Dessouky, R., Gamil, S.A., Nada, M.G., et al. “Management of uterine adenomyosis: current trends and uterine artery embolization as a potential alternative to hysterectomy.” Insights into Imaging 10 (2019). - Zhang, X., Xu, P. “Stratified treatment and management of adenomyosis.” Zhejiang Da Xue Xue Bao Yi Xue Ban 48.2 (2019): 123–9. - Liang, B., Wu, L., Xu, H., et al. “Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: A comparison study in mice.” Reprod Biol Endocrinol 16.1 (2018). - Sukhikh, G.T., Adamyan, L.V., Kozachenko, A.V., et al. “Dydrogesterone for the treatment of confirmed endometriosis: key results of an observational open multicenter study in real clinical practice (ORCHIDEA study).” Obstetrics and gynecology: News. Opinions. Training 4.30.8 (2020): 79–81. DOI: 10.24411/2303-9698-2020-14006 - Guo, S., Zhang, D., Lu, X., et al. “Hypoxia and its possible relationship with endometrial receptivity in adenomyosis: a preliminary study.” Reprod Biol Endocrinol 19.1 (2021). - Higashi, Y., Noma, K., Yoshizumi, M., Kihara, Y. “Endothelial function and oxidative stress in cardiovascular diseases.” Circulation Journal 73 (2009): 411–8. - Guo, S.W. “The Pathogenesis of Adenomyosis vis-à-vis Endometriosis.” J Clin Med 9.2 (2020): 485. - Szefel, J., Danielak, A., Kruszewski, W.J. “Metabolic pathways of L-arginine and therapeutic consequences in tumors.” Adv Med Sci 64.1 (2019): 104–10. - Engeler, D., Baranowski, A.P., Berghmans, B., et al. EAU Guidelines: Chronic Pelvic Pain. Available from: [https://uroweb.org/guideline/chronic-pelvic-pain/#5], last accessed June 25, 2021. - Brainard, A.M., Korovkina, V.P., England, S.K. “Potassium channels and uterine function.” Seminars in Cell and Developmental Biology 18 (2007): 332–9. - Kim, J.M., Song, K.S., Xu, B., Wang, T. “Role of potassium channels in female reproductive system.” Obstetrics and Gynecology Science 63 (2020): 565–76. - Shi, J.-H., Jin, L., Leng, J.-H., Lang, J.-H. “Expression of Potassium Channels in Uterine Smooth Muscle Cells from Patients with Adenomyosis.” Chin Med J (Engl) 129.2 (2016): 200–5. - Sokolova L.K. “L-arginine in norm and pathology. Tivortin.” Available from: [https://tivortin.com/en/specialistam/l-аргінін-у-нормі-та-патології/], last accessed June 25, 2021. - Carrarelli, P., Luddi, A., Funghi, L., et al. “Urocortin and corticotrophin-releasing hormone receptor type 2 mRNA are highly expressed in deep infiltrating endometriotic lesions.” Reprod Biomed Online 33.4 (2016): 476–83. - Carrarelli, P., Yen, C.F., Funghi, L., et al. “Expression of Inflammatory and Neurogenic Mediators in Adenomyosis.” Reprod Sci 24.3 (2017): 369–75. - Zhang, X., Lu, B., Huang, X., et al. “Endometrial nerve fibers in women with endometriosis, adenomyosis, and uterine fibroids.” Fertil Steril 92.5 (2009): 1799–801. - Zhang, X., Lu, B., Huang, X., et al. “Innervation of endometrium and myometrium in women with painful adenomyosis and uterine fibroids.” Fertil Steril 94.2 (2010): 730–7. - Lertvikool, S., Sukprasert, M., Pansrikaew, P., et al. “Comparative Study of Nerve Fiber Density between Adenomyosis Patients with Moderate to Severe Pain and Mild Pain.” J Med Assoc Thai 97 (2014). - Wang, F., Shi, X., Qin, X., et al. “Expression of CD56 in patients with adenomyosis and its correlation with dysmenorrhea.” Eur J Obstet Gynecol Reprod Biol 194 (2015): 101–5. - Stratton, P., Berkley, K.J. “Chronic pelvic pain and endometriosis: Translational evidence of the relationship and implications.” Hum Reprod Update 17.3 (2011): 327–46. Downloads Published How to Cite Issue Section License Copyright (c) 2021 Т.Ф. Татарчук, Л.В. Калугіна, А.О. Данилова, К.С. Павлова This work is licensed under a Creative Commons Attribution 4.0 International License. Authors who publish with this journal agree to the following terms: - Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosischronic_pelvic_paindysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (41)

Cited by (2)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK